Reaction
Hand-Foot-And-Mouth Disease reporting signals
As of the last recalculation, Hand-Foot-And-Mouth Disease appears in 794 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is PALIVIZUMAB (PRR 24.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Palivizumab | 14 | 24.3 | 24.3 |
| Vigabatrin | 13 | 23.8 | 23.8 |
| Cabozantinib | 36 | 20.5 | 20.5 |
| Axitinib | 12 | 16.4 | 16.4 |
| Canakinumab | 5 | 12.2 | 12.2 |
| Crisaborole | 4 | 11.0 | 11.0 |
| Asfotase Alfa | 4 | 10.5 | 10.5 |
| Agalsidase Beta | 3 | 8.5 | 8.5 |
| Dupilumab | 112 | 6.9 | 6.9 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 3 | 6.3 | 6.3 |